Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2017 Summary According to the recently published report 'Exportin 1 - Pipeline Review, H1 2017'; Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli. The report 'Exportin 1 - Pipeline Review, H1 2017' outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Hematological Tumor, Malignant Mesothelioma, Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Amyotrophic Lateral Sclerosis, B-Cell Leukemia, Bone Sarcoma, Burkitt Lymphoma, Cervical Cancer, Chondrosarcoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Duchenne Muscular Dystrophy, Endometrial Cancer, Equine Encephalitis, Fallopian Tube Cancer, Follicular Lymphoma, Gastrointestinal Tract Cancer, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Influenzavirus A Infections, Leiomyosarcoma, Leukemias, Liposarcoma, Lymphoma, Mantle Cell Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Multiple Sclerosis, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Respiratory Syncytial Virus (RSV) Infections, Rheumatoid Arthritis, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Synovial Sarcoma, Systemic Lupus Erythematosus, T-Cell Lymphomas, Thymoma (Thymic Epithelial Tumor), Traumatic Brain Injury, Venezuelan Equine Encephalitis and Waldenstrom Macroglobulinemia. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects - The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Overview Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics Development CanBas Co Ltd Karyopharm Therapeutics Inc Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles KPT-251 - Drug Profile Product Description Mechanism Of Action R&D Progress KPT-276 - Drug Profile Product Description Mechanism Of Action R&D Progress KPT-350 - Drug Profile Product Description Mechanism Of Action R&D Progress KPT-8602 - Drug Profile Product Description Mechanism Of Action R&D Progress selinexor - Drug Profile Product Description Mechanism Of Action R&D Progress SL-801 - Drug Profile Product Description Mechanism Of Action R&D Progress verdinexor - Drug Profile Product Description Mechanism Of Action R&D Progress Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Products Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Product Development Milestones Featured News & Press Releases Jun 07, 2017: Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma May 18, 2017: Karyopharm's Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting Apr 04, 2017: Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801 Dec 15, 2016: Karyopharm and Collaborators Awarded Grant for ALS Research Dec 05, 2016: Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting Dec 04, 2016: Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting Dec 04, 2016: Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting Nov 30, 2016: Karyopharm and the Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders Nov 03, 2016: Karyopharm to Present Updated Phase 2b STORM and Phase 1b STOMP Clinical Data at the American Society of Hematology 2016 Annual Meeting Oct 05, 2016: Karyopharm to Present Updated SIGN Phase 2 Clinical Data at European Society of Medical Oncology 2016 Annual Meeting Sep 29, 2016: Scientists find lethal vulnerability in treatment-resistant lung cancer Sep 28, 2016: Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication Sep 06, 2016: Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma Aug 30, 2016: Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by CanBas Co Ltd, H1 2017 Pipeline by Karyopharm Therapeutics Inc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.